Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
$2.71
+0.6%
$3.06
$1.94
$12.32
$4.06M-0.04125,283 shs25,028 shs
PLx Pharma Inc. stock logo
PLXP
PLx Pharma
$0.00
$0.02
$0.04
$603K3.7912.96 million shs3,000 shs
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
$3.26
0.0%
$3.66
$2.85
$29.44
$5.17M0.0388,525 shs4,783 shs
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$2.18
+2.6%
$1.71
$0.77
$2.27
$216.52M2.311.73 million shs1.40 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
0.00%+2.85%-21.82%+20.22%-57.89%
PLx Pharma Inc. stock logo
PLXP
PLx Pharma
0.00%0.00%0.00%0.00%0.00%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
0.00%-8.69%-14.46%+4.12%-62.86%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
0.00%+11.54%+33.44%+109.13%+90.79%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
PLx Pharma Inc. stock logo
PLXP
PLx Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
0.1627 of 5 stars
0.01.00.00.00.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
0.00
N/AN/AN/A
PLx Pharma Inc. stock logo
PLXP
PLx Pharma
0.00
N/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
0.00
N/AN/AN/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
$11.59M0.35N/AN/A$4.74 per share0.57
PLx Pharma Inc. stock logo
PLXP
PLx Pharma
$4.54M0.00N/AN/A$1.30 per share0.00
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/A($20.31) per shareN/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$1M217.02N/AN/A$0.13 per share16.73
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
-$5.35M-$2.87N/AN/A-43.80%-101.91%-33.75%8/11/2025 (Estimated)
PLx Pharma Inc. stock logo
PLXP
PLx Pharma
-$46.13M-$1.85N/AN/AN/A-606.91%-291.11%-119.43%N/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
-$13.42MN/A0.00N/AN/AN/AN/A8/13/2025 (Estimated)
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$30.88M-$0.38N/AN/AN/AN/A-193.67%-113.02%8/12/2025 (Estimated)

Latest QLGN, SLS, PLXP, and EVOK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$0.1067-$0.07+$0.0367-$0.07N/AN/A
5/12/2025Q1 2025
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
-$0.33-$0.51-$0.18-$0.51$3.32 million$3.08 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/AN/AN/AN/AN/A
PLx Pharma Inc. stock logo
PLXP
PLx Pharma
N/AN/AN/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/AN/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/A
1.55
1.50
PLx Pharma Inc. stock logo
PLXP
PLx Pharma
N/A
4.79
4.28
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/A
4.64
4.64

Institutional Ownership

CompanyInstitutional Ownership
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/A
PLx Pharma Inc. stock logo
PLXP
PLx Pharma
21.19%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
3.18%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
17.38%

Insider Ownership

CompanyInsider Ownership
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
2.29%
PLx Pharma Inc. stock logo
PLXP
PLx Pharma
8.95%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
1.80%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
1.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
41.49 million1.46 millionNot Optionable
PLx Pharma Inc. stock logo
PLXP
PLx Pharma
1629.14 million26.53 millionNot Optionable
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
501.64 million1.61 millionNot Optionable
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
1099.78 million98.38 millionNot Optionable

Recent News About These Companies

Sellas Life Sciences: Tons Of Completed Studies
SELLAS Life Sciences Group, Inc. Common Stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

Evoke Pharma stock logo

Evoke Pharma NASDAQ:EVOK

$2.70 +0.02 (+0.56%)
Closing price 07/3/2025 01:25 PM Eastern
Extended Trading
$2.70 0.00 (-0.18%)
As of 07/3/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

PLx Pharma stock logo

PLx Pharma NASDAQ:PLXP

PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.

Qualigen Therapeutics stock logo

Qualigen Therapeutics NASDAQ:QLGN

$3.26 0.00 (-0.03%)
Closing price 07/3/2025 03:10 PM Eastern
Extended Trading
$3.26 0.00 (-0.09%)
As of 07/3/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

SELLAS Life Sciences Group stock logo

SELLAS Life Sciences Group NASDAQ:SLS

$2.17 +0.06 (+2.59%)
Closing price 07/3/2025 03:52 PM Eastern
Extended Trading
$2.17 0.00 (-0.18%)
As of 07/3/2025 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.